Dr Lal Path Labs posts Q3 FY24 consolidated PAT at Rs. 81.3 Cr

Dr. Lal Path Labs has reported total income of Rs. 557.2 crores during the period ended December 31, 2023

GMM Pfaudler posts Q3 FY24 consolidated PAT at Rs. 31.72 Cr

GMM Pfaudler has reported total income of Rs. 848.28 crores during the period ended December 31, 2023

Industry’s reaction to Union Budget 2024-25

Indian Pharma Post brings together the views of industry leaders on the Interim Union Budget 2024-25 announcement and its impact on the industry

Dabur India posts Q3 FY24 consolidated PAT at Rs. 514.22 Cr

Dabur India has reported total income of Rs. 3382.43 crores during the period ended December 31, 2023

Vimta Labs posts Q3 FY24 consolidated PAT at Rs. 10.13 Cr

Vimta Labs has reported total income of Rs. 82.57 crores during the period ended December 31, 2023

Morepen Laboratories reports Q3 FY24 consolidated PAT at Rs. 31.99 Cr

Morepen Laboratories has reported total income of Rs. 448.62 crores during the period ended December 31, 2023

Orchid Pharma's Exblifeb granted EMA approval

Exblifeb demonstrates remarkable efficacy in treating complicated Urinary Tract Infections (cUTI), pneumonia

Lupin Digital Health introduces digital therapeutics certificate for Cardiologists in India in collaboration with ACC

Sun Pharmaceutical Industries Q3 FY24 consolidated PAT up at Rs. 2,560.54 Cr

Sun Pharmaceutical Industries has reported total income of Rs. 12,630.9 crores during the period ended December 31, 2023

AstraZeneca’s Imfinzi combination shows positive results in phase 3 liver cancer study

About 75% of all primary liver cancers in adults are HCC and up to 30% of HCC patients are eligible for embolisation